Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.
--------
Question: Ice is an example of solid matter. A solid is matter that has a fixed volume and a fixed shape. Figure 4.3 shows examples of matter that are usually solids under Earth conditions. In the figure, salt and cellulose are examples of crystalline solids. The particles of crystalline solids are arranged in a regular repeating pattern. The steaks and candle wax are examples of amorphous ("shapeless") solids. Their particles have no definite pattern. Ocean water is an example of a liquid. A liquid is matter that has a fixed volume but not a fixed shape. Instead, a liquid takes the shape of its container. If the volume of a liquid is less than the volume of its container, the top surface will be exposed to the air, like the oil in the bottles in Figure 4.4. Two interesting properties of liquids are surface tension and viscosity. Surface tension is a force that pulls particles at the exposed surface of a liquid toward other liquid particles. Surface tension explains why water forms droplets, like those in Figure 4.5. Viscosity is a liquids resistance to flowing. Thicker liquids are more viscous than thinner liquids. For example, the honey in Figure 4.5 is more viscous than the vinegar. You can learn more about surface tension and viscosity at these URLs: [Link] [Link] (1:40) MEDIA Click image to the left or use the URL below. URL: Water vapor is an example of a gas. A gas is matter that has neither a fixed volume nor a fixed shape. Instead, a gas takes both the volume and the shape of its container. It spreads out to take up all available space. You can see an example in Figure 4.6. Youre probably less familiar with plasmas than with solids, liquids, and gases. Yet, most of the universe consists of plasma. Plasma is a state of matter that resembles a gas but has certain properties that a gas does not have. Like a gas, plasma lacks a fixed volume and shape. Unlike a gas, plasma can conduct electricity and respond to magnetism. Thats because plasma contains charged particles called ions. This gives plasma other interesting properties. For example, it glows with light. Where can you find plasmas? Two examples are shown in Figure 4.7. The sun and other stars consist of plasma. Plasmas are also found naturally in lightning and the polar auroras (northern and southern lights). Artificial plasmas are found in fluorescent lights, plasma TV screens, and plasma balls like the one that opened this chapter. You can learn more about plasmas at this URL: (2:58). MEDIA Click image to the left or use the URL below. URL: Why do different states of matter have different properties? Its because of differences in energy at the level of atoms and molecules, the tiny particles that make up matter. Energy is defined as the ability to cause changes in matter. You can change energy from one form to another when you lift your arm or take a step. In each case, energy is used to move matter you. The energy of moving matter is called kinetic energy. The particles that make up matter are also constantly moving. They have kinetic energy. The theory that all matter consists of constantly moving particles is called the kinetic theory of matter. You can learn more about it at the URL below. Particles of matter of the same substance, such as the same element, are attracted to one another. The force of attraction tends to pull the particles closer together. The particles need a lot of kinetic energy to overcome the force of attraction and move apart. Its like a tug of war between opposing forces. The kinetic energy of individual particles is on one side, and the force of attraction between different particles is on the other side. The outcome of the "war" depends on the state of matter. This is illustrated in Figure 4.8 and in the animation at this URL: [Link] In solids, particles dont have enough kinetic energy to overcome the force of attraction between them. The particles are packed closely together and cannot move around. All they can do

Answer: state of matter with a fixed volume but not a fixed shape


Question: Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contraction of an array of tandem 3.3-kb repeats (D4Z4) at 4q35. Within each repeat unit is a gene, DUX4, that can encode a protein containing two homeodomains. A DUX4 transcript derived from the last repeat unit in a contracted array is associated with pathogenesis but it is unclear how. Using exon-based microarrays, the expression profiles of myogenic precursor cells were determined. Both undifferentiated myoblasts and myoblasts differentiated to myotubes derived from FSHD patients and controls were studied after immunocytochemical verification of the quality of the cultures. To further our understanding of FSHD and normal myogenesis, the expression profiles obtained were compared to those of 19 non-muscle cell types analyzed by identical methods. Many of the ~17,000 examined genes were differentially expressed (>2-fold, p<0.01) in control myoblasts or myotubes vs. non-muscle cells (2185 and 3006, respectively) or in FSHD vs. control myoblasts or myotubes (295 and 797, respectively). Surprisingly, despite the morphologically normal differentiation of FSHD myoblasts to myotubes, most of the disease-related dysregulation was seen as dampening of normal myogenesis-specific expression changes, including in genes for muscle structure, mitochondrial function, stress responses, and signal transduction. Other classes of genes, including those encoding extracellular matrix or pro-inflammatory proteins, were upregulated in FSHD myogenic cells independent of an inverse myogenesis association. Importantly, the disease-linked DUX4 RNA isoform was detected by RT-PCR in FSHD myoblast and myotube preparations only at extremely low levels. Unique insights into myogenesis-specific gene expression were also obtained. For example, all four Argonaute genes involved in RNA-silencing were significantly upregulated during normal (but not FSHD) myogenesis relative to non-muscle cell types. DUX4's pathogenic effect in FSHD may occur transiently at or before the stage of myoblast formation to establish a cascade of gene dysregulation. This contrasts with the current emphasis on toxic effects of experimentally upregulated DUX4 expression at the myoblast or myotube stages. Our model could explain why DUX4's inappropriate expression was barely detectable in myoblasts and myotubes but nonetheless linked to FSHD.

Answer: Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?


Question: Interleukin-6 (IL-6) has emerged as a key factor in the pathogenesis of the atypical lymphoproliferative disorder Castleman's disease (CD). Siltuximab is a new anti-IL-6, chimeric monoclonal antibody with potential therapeutic benefit in patients with CD. We report interim results from an open-label, dose-finding, seven-cohort, phase I study in which patients with symptomatic, multicentric or unresectable, unicentric CD received siltuximab at 1-, 2-, or 3-week intervals. The main efficacy end point of clinical benefit response (CBR) was defined as a composite of clinical and laboratory measures relevant to the management of CD. In addition, radiologic response was independently assessed by using modified Cheson criteria. Eighteen (78%) of 23 patients (95% CI, 56% to 93%) achieved CBR, and 12 patients (52%) demonstrated objective tumor response. All 11 patients (95% CI, 72% to 100%) treated with the highest dose of 12 mg/kg achieved CBR, and eight patients (73%) achieved objective tumor response. Overall objective-response duration ranged from 44 to > or = 889 days, and one patient had complete response for > or = 318 days. Hemoglobin increased markedly in 19 patients (median increase, 2.1 g/dL; range, 0.2 to 4.7 g/dL) in the absence of transfusion or erythropoiesis-stimulating agents. No dose-limiting toxicity was reported, and only three patients had grade 3 or higher adverse events after a median exposure of 331 days (range, 1 to 1,148 days). These interim results strongly suggest that siltuximab is an effective treatment with favorable safety for the management of CD. An additional study is planned to fully evaluate safety and efficacy at the recommended dose of 12 mg/kg every 3 weeks.

Answer:
Which interleukin is blocked by Siltuximab?